Targeted drug therapy found effective in patients with common form of immune-mediated kidn... ( The drug rituximab causes considerab...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease

Date:8/5/2008

The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that this condition, previously destined to progress to kidney failure in 30-40 percent of cases, can actually be healed in some patients.

Membranous nephropathy (also known as membranous glomerulopathy) is one of the most common immune-mediated kidney diseases, and is thought to be caused by autoimmune reactions against the kidney. The disease, which is characterized by the loss of large amounts of protein in the urine, leads to impaired kidney function that may ultimately require dialysis or renal transplantation.

A variety of immunosuppressive drugs have been tested to inhibit the production of the antibodies that attack the kidneys during the progression of membranous nephropathy, but their effects have been inconsistent. These therapies also can cause significant toxicity and can suppress a patient's immune system, exposing the patient to an increased risk of infections and illnesses.

A new drug called rituximab selectively depletes B lymphocytes, the cells that produce the damaging autoantibodies of membranous nephropathy. The drug was initially developed as a cancer treatment for patients with B cell lymphoma, but kidney researchers have shown that this drug also is safe and reduces the amount of protein lost in the urine due to membranous nephropathy. These same researchers, led by Piero Ruggenenti, MD, of the Negri Bergamo Laboratories in Bergamo, Italy, have now provided evidence that rituximab actually reduces the amount of kidney injury in patients with the disease.

In this study, Dr. Ruggenenti and his colleagues treated 50 patients with membranous nephropathy with rituximab. The investigators found that 10 of the patients event
'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Study suggests brain tumors need treatment with multiple targeted drugs
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Research suggests targeted treatment strategies for lupus
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
6. Gleevec, the targeted cancer pill, delivers more good news to patients
7. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
8. Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
9. A major step toward a more targeted treatment for auto-immune diseases?
10. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
11. New study of targeted therapies for breast cancer -- model for global clinical trials

Post Your Comments:

Breaking Medicine News(10 mins):Health News:Injury Funds Now To the Rescue with New Lawsuit Funding Service 2 Health News:University of Utah Announces New Studies on the Benefits of Treadmill Desks 2 Health News:University of Utah Announces New Studies on the Benefits of Treadmill Desks 3 Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 2 Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 3 Health News:Polar Pump: E85 Fuel Now Available in Warroad, Minn., Northernmost Outlet for the Fuel in USA 2 Health News:Vitamin D Linked to Survival in Lymphoma Patients 2

[0] Injury Funds Now To the Rescue with New Lawsuit Funding Service [0] University of Utah Announces New Studies on the Benefits of Treadmill Desks [1] $12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP)[0] Polar Pump: E85 Fuel Now Available in Warroad, Minn., Northernmost Outlet for the Fuel in USA [0] Vitamin D Linked to Survival in Lymphoma Patients

Abraham Lincoln Presenter to Speak in Tulsa This Saturday Midwest Meets West Coast, The Chicago School of Professional Psychology to Open New Campus in Downtown Los Angeles President Bush Declares March as Red Cross Month EMSI Introduces U-Direct for Life Insurance Direct Marketers Universal Health Services, Inc. Reports 2007 Fourth Quarter and Full Year Earnings and 2008 Guidance As Healthcare Spending is Predicted to Exceed 4 Trillion in Less Than 10 Years, Technology will be Called upon to Stem the Tide

Breaking Medicine Technology:Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2 Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5 Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6 BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2 BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3 BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4 Hispanic Workers Ages 50+ May Help Employers Solve Potential Future Labor Shortages 48195 1 Hispanic Workers Ages 50+ May Help Employers Solve Potential Future Labor Shortages 48195 2 Hispanic Workers Ages 50+ May Help Employers Solve Potential Future Labor Shortages 48195 3 Robot Speaks Many Languages Improves Pharmacy Patient Outcomes 48192 1 Robot Speaks Many Languages Improves Pharmacy Patient Outcomes 48192 2 Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 1 Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 2 Medical Home Pilot Initiatives Continue to Expand Nationwide 48189 3

[0] Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix [0] Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase [0] BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors

Other Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2 Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3 Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4 Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 2 Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 3

Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease

Medicine Products:

ENDO STITCHtrade; Short 10 mm Suturing Device ENDOKNOT Suture Type - 0 Coated VICRYL ENDOLOOP Suture Type - 0 MONOCRYL ENDOLOOP Ligature Type - 0 Chromic Gut

Targeted drug therapy found effective in patients with common form of immune-mediated kidn...( The drug rituximab causes considerab...),Health